Q-omics provides the consensus-scored URGCP-MRPS24 profile across patient tissues and cancer cell-line models. URGCP-MRPS24 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, URGCP-MRPS24 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, URGCP-MRPS24 RNA expression shows 11,630 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KIRC, and TGCT as cancer lineages where URGCP-MRPS24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for URGCP-MRPS24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes URGCP-MRPS24 survival associations across molecular data types. URGCP-MRPS24 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible URGCP-MRPS24 RNA expression–survival associations across cancer types. High URGCP-MRPS24 expression shows unfavorable associations in SCLC, COAD and KICH, but favorable associations in KIRP, KIRC and PAAD. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for URGCP-MRPS24 RNA expression.
This table summarizes URGCP-MRPS24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for URGCP-MRPS24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. URGCP-MRPS24 shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in HNSC, CHOL and LIHC. The KIRC box plot shows higher URGCP-MRPS24 RNA expression in normal versus tumor tissue (log2 FC = −0.130, t-test p < 0.001).
This table shows molecular features associated with URGCP-MRPS24 in patient tissues and cancer cell lines. In patient samples, URGCP-MRPS24 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, URGCP-MRPS24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma.
